Research Funding Available
Fibrolamellar Cancer Foundation

The Fibrolamellar Cancer Foundation (FCF) has announced a major call for proposals to support innovative research, leading to curative treatments for this aggressive teen/young adult liver cancer.

Importantly, ASCO and other major organizations have noted investigators should take high interest in this cancer, as due to patient age this is a relatively simple cancer, i.e. few mutations, which potentially allows applications to other diseases as well.

Introduction
The Fibrolamellar Cancer Foundation (FCF) is a public, non-profit organization established primarily to support the funding of research related to Fibrolamellar Hepatocellular Carcinoma. FCF is also committed to raising awareness about this disease through education and marketing across all stakeholders, as well as fostering a global community of patients and caregivers - for all suffering from, and caring for, this rare liver cancer

www.fibrofoundation.org

About Fibrolamellar Hepatocellular Carcinoma (FL-HCC):

- Very rare form of liver cancer that usually occurs in teens/young adults who have no history of liver disease.
- Approximately 300 people are diagnosed with this cancer worldwide- and often at Stage IV
- Patients typically present with a palpable abdominal mass but no symptoms, although pain, weight loss and jaundice may occur.
- The standard initial treatment is surgical removal of the tumor. When the tumor cannot be removed surgically or when there is distant spread, chemotherapy, and most recently immunotherapy is used.
- While several new innovative therapies are being researched, still today there is no standard regimen - and the two year mortality rate continues at an alarming average of 90%.

Eligibility
Applicants must be employed by an institution engaged in health related research. The applicant further must agree to be supervised by the institution at all times while conducting research supported by the FCF. In cases of a change in institutions while applying for, or utilizing funds from the FCF, applicants must notify the FCF, and will be subject to review based upon the change in circumstances.

The research must focus on Fibrolamellar Hepatocellular Carcinoma. Studies should be intended to advance knowledge in the areas of FL-HCC. Of particular interest are those showing a clear path to clinical trials.

Collaboration and open sourcing is a requirement for FCF funding and will be so specified in any grant agreement.

RFP application information is attached, and also available at www.fibrofoundation.org or email us at grants@fibrofoundation.org

Grant Review Periods
FCF has a semiannual review period with application deadlines of January 1st and July 1st. The foundation is open to time sensitive requests - particularly for truly innovative ideas- throughout the year, as exceptions.